Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

Ovulation induction (OI) using gonadotropins is one of the most widely prescribed treatments of infertility. One common problem encountered while attempting OI using gonadotropins is premature ovulation. The purpose of this study is to examine the effect of a single injection of a medication, called ganirelix, to prevent premature ovulation. Patients will be divided into two groups. In the first group, gonadotropins will be used to stimulate the ovaries. In the second group gonadotropins will be used in addition to a single injection of ganirelix, a gonadotropin releasing hormone (GnRH) antagonist. Pregnancy rates will be compared between groups.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Houston Fertility Institute
• Treatments: Ganirelix

Criteria

Inclusion Criteria:

• Patients undergoing ovulation induction (OI) between ages 18 - 39 years.

• One or more of the following infertility diagnoses: ovulation dysfunction, mild male factor infertility (sperm concentration of 5- 20 million/ml, and/or sperm motility 10%
• 40%) , absence teratospermia (i.e. strict morphology > 4%), unexplained infertility.

• Patent Fallopian tubes.

• Normal uterine structure (i.e. absence of mullerian anomalies)

• Ability to consent to the study.

• Patients should be Houston Fertility Institute patients

Exclusion Criteria:

Exclusion criteria include:

• Age 39 or above

• Severe male factor (concentration < 10 million/ml or strict morphology < 4%)

• Obstructed Fallopian tubes on one or both sides

• Stage III or IV endometriosis

• Elevated FSH level (>10 IU/L)

• Low antral follicular count (< 4 antral follicles per ovary)

• Any other contraindication for ovulation induction

• Inability to consent to the study

• History of any prior failed OI/IUI cycle